



(11)

EP 2 286 794 B8

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
A61K 9/127 ^(2006.01) **A61K 31/335** ^(2006.01)
A61P 35/00 ^(2006.01) **A61K 31/00** ^(2006.01)

(48) Corrigendum issued on:
01.06.2016 Bulletin 2016/22

(45) Date of publication and mention
of the grant of the patent:
30.03.2016 Bulletin 2016/13

(21) Application number: **10180750.1**

(22) Date of filing: **15.10.2004**

(54) **USE OF CATIONIC LIPOSOMES COMPRISING PACLITAXEL**

VERWENDUNG VON KATIONISCHEN LIPOSOMEN MIT PACLITAXEL

UTILISATION DE LIPOSOMES CATIONIQUES AVEC PACLITAXEL

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PL PT RO SE SI SK TR

(30) Priority: **15.10.2003 EP 03023539**
09.01.2004 EP 04000361

(43) Date of publication of application:
23.02.2011 Bulletin 2011/08

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
04790494.1 / 1 673 069

(73) Proprietor: **SynCore Biotechnology CO., LTD**
Tung Shan Shine, I-Lan (TW)

(72) Inventors:
• **Teifel, Michael**
64331, Weiterstadt (DE)
• **Michaelis, Uwe**
82362, Weilheim (DE)
• **Sauer, Birgitta**
82166, Gräfelfing (DE)
• **Bartelheim, Kerstin**
82269, Walleshausen (DE)

• **Brunner, Christoph**
82387 Antdorf (DE)

(74) Representative: **Weickmann & Weickmann**
PartmbB
Postfach 860 820
81635 München (DE)

(56) References cited:
WO-A-01/17508 WO-A-98/40052
WO-A-2004/002455 WO-A-2004/002468
US-A- 6 090 955

• **CAMPBELL R B ET AL: "INFLUENCE OF**
CATIONIC LIPIDS ON THE STABILITY AND
MEMBRANE PROPERTIES OF
PACLITAXEL-CONTAINING LIPOSOMES"
JOURNAL OF PHARMACEUTICAL SCIENCES,
AMERICAN PHARMACEUTICAL ASSOCIATION.
WASHINGTON, US, vol. 90, no. 8, August 2001
(2001-08), pages 1091-1105, XP001101828 ISSN:
0022-3549

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 286 794 B8

- EMERSON D L: "Liposomal delivery of camptothecins" PHARMACEUTICAL SCIENCE AND TECHNOLOGY TODAY, ELSEVIER TRENDS JOURNALS, CAMBRIDGE,, GB, vol. 3, no. 6, 1 June 2000 (2000-06-01), pages 205-209, XP002235822 ISSN: 1461-5347

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification